[Therapeutic possibilities in systemic scleroderma].
Sönnichsen
N
N
Dermatologische Klinik und Poliklinik, Medizinischen Fakultät (Charité), Humboldt-Universität zu Berlin.
Brenke
A
A
D000974:Antibodies, Antinuclear / Q000032:analysis; D001323:Autoantibodies / Q000032:analysis; D001379:Azathioprine / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D006801:Humans; D010396:Penicillamine / Q000008:administration & dosage; D026741:Physical Therapy Modalities / Q000379:methods; D011239:Prednisolone / Q000008:administration & dosage; D012595:Scleroderma, Systemic / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D014665:Vasodilator Agents / Q000008:administration & dosage
D000974:Antibodies, Antinuclear; D001323:Autoantibodies; D014665:Vasodilator Agents; D011239:Prednisolone; D010396:Penicillamine; D001379:Azathioprine
Therapeutische Möglichkeiten bei der systemischen Sklerodermie.